ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,564.41
1.08%
US Tech 100
19,270.40
1.37%
Dow Jones
40,415.44
0.32%
Brent Oil
81.515
-0.93%
Bitcoin
67,710.94
-0.65%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Revance Therapeutics Inc (RVNC) Quote

Revance Therapeutics Inc

Revance Therapeutics Inc (RVNC)

NASDAQ
4.01
0.375
(10.32%)
At close: July 22 4:00PM
Delayed by 15 minutes
4.1884
0.1814
( 4.53% )
After Hours: 6:00PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
4.1884
Bid
4.04
Ask
4.23
Volume
1,632,921
3.605 Day's Range 4.145
2.30 52 Week Range 24.87
Market Cap
379.67M
Previous Close
3.635
Open
3.69
Last Trade
100
@
4.1884
(formt)
Last Trade Time
17:54:43
Financial Volume
$ 6,360,415
VWAP
3.8951
Average Volume (3m)
1,927,428
Shares Outstanding
104,448,502
Dividend Yield
-
PE Ratio
-1.29
Earnings Per Share (EPS)
-3.1
Revenue
234.04M
Net Profit
-323.99M

About Revance Therapeutics Inc

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD pl... Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.revance.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Revance Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RVNC. The last closing price for Revance Therapeutics was $3.64. Over the last year, Revance Therapeutics shares have traded in a share price range of $ 2.30 to $ 24.87.

Revance Therapeutics currently has 104,448,502 shares outstanding. The market capitalization of Revance Therapeutics is $379.67 million. Revance Therapeutics has a price to earnings ratio (PE ratio) of -1.29.

RVNC Latest News

More News

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units (“RSUs”) to 31 employees. The RSUs vest over four...

June 14 2024
Business Wire

Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced that the company will be participating in the following investor conferences. William Blair 44th Annual Growth Stock Conference Chief...

May 28 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 09 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 09 2024
Edgar (US Regulatory)

Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a...

May 09 2024
Business Wire

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

DAXXIFY® for the treatment of cervical dystonia is the first and only peptide-formulated, long-lasting neurotoxin that offers the potential to improve duration of symptom control1 Revance has...

May 09 2024
Business Wire

Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results...

May 02 2024
Business Wire

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one...

April 12 2024
Business Wire

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units (“RSUs”) to 29 employees. The RSUs vest over four...

March 27 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

March 08 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.518414.12534059953.674.3783.440222012763.90389551CS
41.488455.12592592592.74.3782.317415923.2000028CS
120.738421.40289855073.454.4752.319274283.19773943CS
26-1.5316-26.77622377625.727.562.318561604.30592601CS
52-18.9816-81.923176521423.1724.872.318328027.96657723CS
156-26.5916-86.392462638130.7837.982.3133750416.50646447CS
260-8.4616-66.890118577112.6537.982.3102260817.86379771CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LIFWMSP Recovery Inc
$ 0.775
(57.49%)
2.67M
FEIMFrequency Electronics Inc
$ 13.56
(31.65%)
40.19k
TUSKMammoth Energy Services Inc
$ 4.46
(28.16%)
17.81k
BIVIBioVie Inc
$ 0.49
(16.14%)
344.67k
LUXHLuxUrban Hotels Inc
$ 0.165
(13.36%)
62.74k
RNAZTransCode Therapeutics Inc
$ 0.49
(-38.17%)
197.53k
CMAXCareMax Inc
$ 4.3101
(-16.95%)
964.88k
MEDPMedpace Holdings Inc
$ 367.50
(-15.94%)
13.33k
MIRAMIRA Pharmaceuticals Inc
$ 4.28
(-14.57%)
9.52M
XCURExicure Inc
$ 0.4326
(-13.45%)
63.34k
MIRAMIRA Pharmaceuticals Inc
$ 4.28
(-14.57%)
2.97M
LIFWMSP Recovery Inc
$ 0.775
(57.49%)
2.67M
PRSTPresto Technologies Inc
$ 0.065
(-3.27%)
1.24M
SQQQProShares UltraPro Short QQQ
$ 8.121
(0.51%)
1.12M
SLNASelina Hospitality PLC
$ 0.0364
(0.00%)
965.43k

RVNC Discussion

View Posts
vinmantoo vinmantoo 3 hours ago
Nice to see that the RVNC roller coaster has resumed its upward swing.
🫡 1
apm_com apm_com 4 hours ago
Perhaps a little insight from a competitor on Q2 activity and 2nd half potential:

Evolus to Report Second Quarter Financial Results on July 31, 2024
Business Wire
NEWPORT BEACH, Calif.-(BUSINESS WIRE) --Evolus, Inc. (EOLS.NaE), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close.
Evolus (EOLS.NaE) management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.)
👍️0
Tomdontworry Tomdontworry 2 days ago
If all holds true, we should find out China’s first approval by 8/13.
👍️0
rock mountain rock mountain 2 days ago
Fosun made two press releases in April and July 2023 in regard to the submission of Daxxify, for cosmetic treatment and the treatment of cervical dystonia, stating that China's NMPA accepted both applications for review. Other source state that median approval for compounds was 15,4 months (2017 -2021). Generally imported drugs take longer but the trend for approval times is going down. My guess is thus that we will see approval this Q3 or Q4 - and yes I agree that we will not see a significant impact of royalty payments from Fosun this FY. Buckle-up for 2025 as RVNC will make a significant impact in relaxing those necks in the PR of China.
👍️ 2 😂 2
go seek go seek 3 days ago
Also beyond approval milestone payment(s)
I doubt Revance will receive royalty revenue from (China) Daxi sales this year.
👍️0
DewDiligence DewDiligence 3 days ago
Fosun Pharma will issue a press release when China's NMPA approves Daxxify for marketing.
👍️ 2
Jab44 Jab44 3 days ago
It comes from the NMPA. I’m not sure exactly whether they share the approval on line .
👍️0
Jlinvest01 Jlinvest01 3 days ago
If approved, does the company have to report it? They could keep it for themselves and mix it into Q2 report. Which wouldn't be a positive.
Any ways to track china approvals directly?
👍️0
Jab44 Jab44 3 days ago
That is what I’m waiting for. It would be a boost to get the registration before announcing second quarter results. Of course when Abbvie announces the analytics begin with extrapolating the Botox loss of market share and who is capturing it.
👍️ 1
rock mountain rock mountain 3 days ago
Any news on the registration in the PR of China? That should be a big boost.
👍️0
Jlinvest01 Jlinvest01 3 days ago
Question is, what would the board do, in case of an unsolicited offer at this stage? Management would have to present it to them. If board would decide to launch request to other parties, they would have to pr it, and things could move up a lot real fast.
👍️ 1
Kydg Kydg 4 days ago
How about Abbvie sales?
👍️ 2
Emannow Emannow 4 days ago
Just like J&J who bought Mentor Breast implants and is now the #1 breast implant company in the WORLD (destroyed Allergan breast market share) RVNC will be bought by a large Pharma company, and Daxi will become the #1 toxin in the world!

It is short sighted for AbbVie to short RVNC. The Allergan executive management team is leaving one after another in the last 12 months. The management team sees the writing on the wall and knows Botox which is 20 plus yrs old and Juvederm will continue to lose market share! Allergan is not filling many positions when executives leave! Allergan is cutting costs to try and match decreasing revenues!
👍️ 1
Kydg Kydg 4 days ago
RVNC is the only one with unique and better products. The others are all botox biosimilars but their market cap is higher than RVNC. That makes 0 sense.

Keeping RVNC share prices extremely low is their only chance to survive. If SP goes above 10$,and RVNC raise 200m,in 2 years RVNC will kill all competitors.
👍️ 3
Emannow Emannow 4 days ago
Totally agree! AbbVie is highly shorting RVNC to keep the SP low in an effort to bankrupt RVNC so RVNC can not raise funds by selling shares! Abbive knows Daxi is replacing Botox in many accounts!

Just did an analysis with a large practice (annual Allergan purchases of $700,000 plus) which was 100% Botox and Juvederm for the last 15 yrs and over the last 9 months switched to Daxi and RHA. Their gross toxin revenue is down 6% but their toxin net profit is up 9%. They are making more profits off each patient. Additionally, variable and fixed costs are also down 8% and the injectors now have free patient space to fill over the next 12 months as they convert new patients and the USA toxin market grows 12 to 14%. They Love, love RHA and completely eliminated Juvederm. Patients LOVE Daxi and do not want Botox..this practice has completely eliminated the need for the Allergan rep in the office. Allergan knows this will happen!!!
👍️ 4 💯 1
go seek go seek 4 days ago
RVNC’s share price is kept low by competitors, I believe.
I doubt it.
👍️0
Jlinvest01 Jlinvest01 4 days ago
Shorts won't scare until we break 150dma. Below = no brrainer reload for them / Higher = they run for hills.
Might not happen in Q2, but therapeutics sales have a lot of upwards potential. Company took conservative approach because of aestethics set backs. But i strongly believe that dynamics will be different on therapeutic side.
👍️ 1
Kydg Kydg 4 days ago
RVNC’s share price is kept low by competitors, I believe.
👍️ 1
vinmantoo vinmantoo 4 days ago
Doesn't matter.

I was just joking. I didn't mean to suggest I was upset or worried. Someone whose name won't get mentioned made uninformed, reckless and inaccurate comments about Taiwan a day or two ago and the Chip/AI sector got crushed and drove the market down. Looks like that trend is continuing somewhat today.

Need good data to break the 150/200 dma. Without it, these lines will remain a glass ceiling. All hinges on execution by management. The product took shares to 40+, execution took it to 2$.

We are on the same page.
👍️0
Jlinvest01 Jlinvest01 4 days ago
Doesn't matter. Need good data to break the 150/200 dma. Without it, these lines will remain a glass ceiling. All hinges on execution by management. The product took shares to 40+, execution took it to 2$.
👍️0
go seek go seek 4 days ago
and easy come again… more easy come than easy go! 😂
👍️0
vinmantoo vinmantoo 4 days ago
Uh oh, easy come, easy go.
👍️0
DewDiligence DewDiligence 5 days ago
Re: AEON I am puzzled by the substantial increase in AEON's stock price… You have to put it in perspective. AEON is still down sharply from its closing price on 5/2/24, the day before they reported the failed phase-2 trial in migraine prevention (#msg-174352699). In my opinion, there is little to anticipate from CD, given [ABP-450’s] comparable duration to Botox. AEON is pursing CD because they think it’s the most direct route to FDA approval of ABP-450 as a Botox biosimilar. Note that AEON has to stick to therapeutic indications because EOLS owns the commercial rights to the drug in aesthetic indications. (AEON’s ABP-450 and EOLS’ Jeuveau are the exact same drug.)

As noted in #msg-174726891, AEON is nearly insolvent and hence it’s hard to see how they complete a phase-3 trial to obtain FDA approval using the 351(k) pathway. It’s possible that the recent bounce in the share price stems from a leak that such funding is forthcoming from somewhere.
👍️ 3
ASPRV ASPRV 5 days ago
Is there an alternative method to forecast Daxxify revenue aside from monitoring Instagram or TikTok trends?

I'm frustrated with the volatility following earnings reports.

I recently acquired additional shares at $2.80, but this hasn't significantly lowered my average price.

Additionally, I am puzzled by the substantial increase in AEON's stock price. In my opinion, there is little to anticipate from CD, given its comparable duration to Botox. Furthermore, they were unsuccessful in the migraine market.
👍️0
TechandBio TechandBio 5 days ago
Revance my modest options from 2 weeks ago are up 123% also adding shares of ICCM curing early and later stage breast cancer patients with 97% complete response rate after 5 years. reminds me of PLSE when i started buying shares at 1.30s a few years ago,

$RVNC
👍️0
Jlinvest01 Jlinvest01 5 days ago
Q2 numbers only need to show that trajectory (either sales or volume, but prefereably volume) to break even by eoy '25, is intact. This, and only this will scare them shorts. From 2$ to 4$ is nothing, merely a correction of an overreaction.
👍️ 1
biotech_researcher biotech_researcher 5 days ago
It was about time for a re-test..
👍️ 1
go seek go seek 6 days ago
Revance shorts need to cover, the Big Squeeze is on!
👍️ 2
apm_com apm_com 6 days ago
4 handle nice, but some 0’s behind it.. then we get to proper value! Gaining traction, q2 improvement, but more of a 25’ story!! Kinda pissed that my 2.5/5 strikes might/won’t get exercised(ex-RVNC10/18/2024 2.50 PUT REVANCE THERAP)
RVNC
10/18/2024 2.50 PUT
REVANCE
THERAPEU-TICS
+$115.00(13.86%)
$0.45-
$0.15-30

Long game, decent balance sheet, traction !!
👍️0
rock mountain rock mountain 6 days ago
merci mouton
👍️0
SuperAstrologer43 SuperAstrologer43 6 days ago
Nice breakout on the weekly bullish falling wedge Next is $8 if $4 holds...
👍️ 1
vinmantoo vinmantoo 6 days ago
Oooh, RNVC broke $4 this morning on strong volume, the 3rd day in a row of higher than normal volume. 😀 RVNC may not close over $4 today but it is nice to see while eating breakfast.
👍️ 3 🤝 2
alphahelix1 alphahelix1 6 days ago
FogPharma is developing drugs using stapled peptides, see FogPharma.com
👍️0
biotech_researcher biotech_researcher 6 days ago
Every day is the way……
👍️0
mouton29 mouton29 7 days ago
Here’s an article discussing cell penetrating peptides. https://www.tandfonline.com/doi/full/10.1080/17425247.2023.2251399

Introduction
Cell-penetrating peptides (CPPs), are small peptides that facilitate cytosolic access and, thus, transport of therapeutic macromolecules to intracellular sites when conjugated to cargo proteins. As with all new delivery platforms, clinical development of CPP-containing therapeutics has faced considerable challenges.

Areas covered
RTP004 is a novel, 35–amino acid, bi-CPP-containing excipient that binds noncovalently with its cargo (botulinum toxin type A) rather than conjugated as a fusion protein. An RTP004-containing neurotoxin formulation, daxibotulinumtoxinA-lanm for injection (DAXI), has recently been approved by the FDA. The formulation and pharmacological characteristics of RTP004 and the efficacy and safety of the RTP004-neurotoxin formulation are discussed.
👍️ 3
rock mountain rock mountain 7 days ago
Cell penetrating peptide: DAXXIFY is the only botulinum toxin with cell penetrating peptide technology (1, 6-10). On the RVNC website in the cervical dystonia chapter, one can find the latter statement. I never heard the claim of "cell penetration" before. The references after this statements are the prescription informations of Daxxi and of the other bot. toxins - not any article in a learned journal. Have I fallen asleep behind the wheeel - thus far the story of the adjuvant was its postive charge which thus allowed the toxin to remain close the negatively charged cell surface, allowing for better endocytosis. I never read anywhere that the adjuvant aids in cell penetration. Cell penetration from outside directly into the cytoplasm? Is this just a marketing message, keep it simple? For medical products any statement needs to be backed up with published facts - are there any? Anybody know? Thanks Rockmountain
👍️0
go seek go seek 1 week ago
Giddyap Revance! 🚀
👍️ 2
biotech_researcher biotech_researcher 1 week ago
Fake Botox story:
https://apple.news/AI8_eZfUHTmmFhOlMPqsLog
👍️0
biotech_researcher biotech_researcher 1 week ago
Stop arguing and just listen to it, for crying out loud…
👍️ 2
Hitman970 Hitman970 1 week ago
I get the point. And will re state that podcasts are not footnoted.
🤡 1
biotech_researcher biotech_researcher 1 week ago
“Podcasts are not due diligence “

You completely missed the point of the post. Podcasts that explain how teens are embracing their facial look using cosmetic compounds like Botox, and naturally Daxxi
👍️0
vinmantoo vinmantoo 1 week ago
I have to say that seeing RVNC finally reverse course and rise this week has been a relief. I sure hope this is the start of something big. My last buy two weeks ago at $2.33 is looking pretty good.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174668146

My last buy was a month before that at $2.70 which isn't looking bad now either. I won't mention my previous buys over the past year as much higher prices for some reason. :) or is it :0

While I am still down 35% on my RVNC investment, being down 35% today feels a low better than being down some 60%. I also booked some tax losses so that makes me feel a bit better too. I have far more RVNC shares now than I have before the big, sustained and painful drop of RVNC so that means my future gains, if they keep coming, will be amplified.
👍️ 4 🫡 3
vinmantoo vinmantoo 1 week ago
Podcasts are not due diligence

Correct. Clinical trials showing Daxxify is superior to Botox.
👍️ 2
Hitman970 Hitman970 1 week ago
Podcasts are not due diligence
🤡 1
biotech_researcher biotech_researcher 1 week ago
More customers:

https://podcasts.apple.com/us/podcast/short-wave/id1482575855?i=1000661952963
👍️0
stocksrising stocksrising 1 week ago
Agreed, and it’s more about Cash Flow positive/neg( gaap) than analyst estimates of eps…
Toby will most likely reaffirm 2025 expectations, but would love to hear if it’s 1st half or 2half( don’t he’ll go that far)
👍️ 1
go seek go seek 2 weeks ago
There’s no way on God’s Green Earth, interest rates will be 2-3% by late 2025.
👍️ 2
SuperAstrologer43 SuperAstrologer43 2 weeks ago
Someone should ask at earning calls whether they have enough cash to last to profitable Q4 2025. Unless sales are growing exponentially which is entirely possible with people switching over from Botox from words of mouth. Otherwise seems another round of financing is possible. I hope Fed can lower interest in time to 2-3% for them to refinance and don't have to dilute more shares when we pop to $5
👍️0
stocksrising stocksrising 2 weeks ago
Welcomed :)
Likely due to Russell 2k surpassing Feb 22’ highs
( lower rate prospects possibly by Sept.)

Short covering (perhaps channel checks showing traction) ( here in Palm Beach County better adaption by some friends in the biz)

And simply EV was mispriced and Mr. Market properly making the adjustments :)

Not out of the woods, but glad to see $3’s and hopefully more after Q2 report ( many brokers force 100% equity if under 3—fortunately I only use margin in 1 of the few accounts that hold RVNC)

I saw estimates (I believe it’s from ML ) has a .36 loss for Q2…. And by Q4, 25’ sort of b/e
2024
Q2-0.36
Q3-0.3325
Q4-0.2847

2025
Q1-0.2199
Q2--0.1593
Q3-0.098
Q4-0.063

For me, I’m in very long term and sell naked puts and hope it gets exercised :)….2025/26 story
👍️ 1
go seek go seek 2 weeks ago
New instagram ad… today.
https://www.instagram.com/reel/C9SpkI0xEkP/?igsh=bGdoeWdrZW5rbjht
👍️ 2

Your Recent History

NASDAQ
RVNC
Revance Therapeutics
NASDAQ
ARGX
argenx
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved